Search

Changes to Formulary as of  30th September 2020:

BNF Category Number

Product/indication

Detail of change

9.1.4

Avatrombopag

Added as RED drug and added link to NICE TA626

4.7.4.2

Fremanezumab

Added as Unclassified and added link to NICE TA631

8.1.5

Trastuzumab emtansine

Added link to NICE TA632

1.5.3

Ustekinumab

Added link to NICE TA633

8.1.5

Daratumumab

Added link to NICE TA634

8.1.5

Ramucirumab

Added link to NICE TA635

9.1.3

Eculizumab

Added link to NICE TA636

11.8.2.3

Ranibizumab

Added link to NICE TA637

8.2.4

Atezolizumab

Added link to NICE TA638 and NICE TA639

5.3.6

Remdesivir

Moved to chapter 5.3.6 and added link to NICE ES27

9.6.4

Vitamin D

Added link to NICE ES28

8.4.4.2, 6.4.2 and 6.8

Cyproterone acetate: new advice to minimise risk of meningioma

Added link to MHRA Drug Safety Update

2.8.2

Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents

Added link to MHRA Drug Safety Update

8.1.5

Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection

Added link to MHRA Drug Safety Update

 

Liposomal and lipid-complex formulations: name change to reduce medication errors

Added link to MHRA Drug Safety Update

1.7.4

GTN 0.4% Ointment

Changed from AMBER SI to GREEN drug

6.1.1.2

Toujeo Doublestar Pen

Added as NOT APPROVED drug

1.9

Telotristat

Added as NOT APPROVED drug

6.1.2.3

Saxagliptin

Removed from the formulary for new patients

15.1.4.2

Alfentanil 5mg/ml injection

Removed from the formulary for palliative care use

1.3.5

Omeprazole suspension

Change to licensed 2mg/ml product

2.12

CD&T APC Position Statement on Omega-3 Prescribing

Added link

4

CD&T APC Pain Management Guidance for Non-Cancer Pain in Primary Care

Added link

 

CD&T APC Do Not Prescribe/Grey List

Links throughout formulary updated